Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.

Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.

Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.

Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.

Breast oncologists discuss how they weigh the efficacy of anticancer treatment with the possibility of a treatment-related adverse event, like chemotherapy-induced neutropenia.

Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.

Recommendations for intervening with growth factor support and important considerations for reducing or discontinuing anti-cancer therapy when patients show signs of neutropenia.

Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.

Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.

Variables that oncologists should consider when determining when to initiate prophylactic therapy for chemotherapy-induced neutropenia in patients with breast cancer.

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.

Aditya Bardia, MD, MPH, leads the discussion on the use of novel CDK4/6 inhibitors, BCL2 inhibitors, and oral SERDS for the treatment of HR+ metastatic breast cancer.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.

Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.

Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.

Dejan Juric, MD, leads the discussion on the role of PIK3CA mutations in HR+ metastatic breast cancer.

Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.

A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.